Krystal Biotech announced $116.4 million in global revenue for Q1 2026, a 32% increase year-over-year, driven by its gene therapy product VYJUVEK for dystrophic epidermolysis bullosa. The company completed enrollment in a key registrational study for KB803 and expects data readouts for KB803 and KB801 later in 2026. The FDA granted platform technology designations for KB407 and KB111, potentially accelerating development. Krystal ended the quarter with $1 billion in cash and investments, supporting ongoing trials and global expansion efforts.
STMicroelectronics announced a $1.5 billion issuance of new convertible senior bonds in two tranches, with maturities of 5 and 7 years, alongside the early repayment of $750 million of zero-coupon convertible bonds due in 2027. The new bonds offer fi...
Regentis Biomaterials shares surged over 500% intraday before falling 9.15% in after-hours trading following the company's announcement that it withdrew its Registration Statement for a public offering. The regenerative medicine firm decided not to p...
Elon Musk's SpaceX recently went public, raising questions about a potential IPO for its Starlink subsidiary. Data from prediction market Kalshi shows only a 7-10% chance of a Starlink IPO announcement before mid-2027. Meanwhile, Musk predicts SpaceX...
Goodfirms has published its 2026 rankings of top technology service providers across six categories: mobile app, software, web development, digital marketing, SEO, and AI development. These rankings are based on over 1.2 million verified client revie...
Alvotech announced a $152 million public offering and concurrent private placement of ordinary shares priced at $3.75 each. The public offering includes 22.7 million shares, with an option for underwriters to buy an additional 3.4 million shares. The...
